Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Histone Variant Linked to Melanoma Progression

By LabMedica International staff writers
Posted on 03 Jan 2011
Development and spread of melanoma has been linked to the loss of a specific histone isoform.

Histones are highly alkaline proteins found in eukaryotic cell nuclei, which package and order the DNA into structural units called nucleosomes. More...
They are the chief protein components of chromatin, act as spools around which DNA winds, and play a role in gene regulation. Although increasing evidence has demonstrated that tumor progression entails chromatin-mediated changes such as DNA methylation, the role of histone variants in cancer initiation and spread has been unclear.

In the current study, investigators at the Mount Sinai School of Medicine (New York, NY, USA) focused their attention on the histone variant macroH2A (mH2A). They reported in the December 23, 2010, issue of the journal Nature that macroH2A suppressed tumor progression of malignant melanoma.

Working with melanoma cells growing in culture and with a mouse model, they showed that knockdown of mH2A isoforms in melanoma cells of low malignancy resulted in significantly increased proliferation and migration in vitro and growth and metastasis in vivo. Restored expression of mH2A isoforms reversed this trend in both cell cultures and the animal model.

The investigators found that at the molecular level the tumor-promoting function of mH2A loss was mediated, at least in part, through direct transcriptional increase of the enzyme CDK8 (cyclin-dependent kinase 8), a known oncogene for colorectal cancer.

"We wanted to determine whether macroH2A is a passenger in this process or if it is crucial in the progression of melanoma,” said senior author Dr. Emily Bernstein, assistant professor of oncological sciences and dermatology at Mount Sinai School of Medicine. "CDK8 is highly expressed in aggressive melanoma, suggesting it also plays a major role in the process.”

"Very little is known about melanoma epigenetics or the histone-mediated epigenetic changes in cancer in general, so these findings are a major step forward in our research. As we move ahead, we would like to determine how to inhibit CDK8 function, thereby inhibiting the growth of melanoma, as well as identify additional epigenetic changes in melanoma progression,” said Dr. Bernstein. "What these discoveries really highlight is the need for further studies into the epigenetic code of cancer.”

Related Links:
Mount Sinai School of Medicine



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.